Business / Finance

RSS

Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

Key appointment to lead global commercial launch of eProtein Discovery platform

From Nuclera 14 Mar 2024

Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement

...

From ERS Genomics 13 Mar 2024

World Vaccine Congress draws leaders from government, science and industry

Sessions cover topics from cancer vaccines to logistics and the next.

From World Vaccine Congress Washington 13 Mar 2024

Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation

Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa study.

12 Mar 2024

Metrion Biosciences strengthens team with three key appointments

Clare Rutty promoted to CFO, Sue Peffer appointed Head of Marketing, Leanne Clarke appointed HR Officer.

From Metrion Biosciences Limited 11 Mar 2024

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

From Ubiquigent Limited 11 Mar 2024

New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution

New bisulfite-free system allows scientists to accurately and sensitively discriminate 5hmC from un-modified cytosine and 5mC from a wide range of DNA inputs, advancing epigenetics research.

From New England Biolabs 8 Mar 2024

INTEGRA supports the next generation of synthetic biologists

INTEGRA Biosciences awarded 3 PIPETBOY acu 2 serological pipette controllers to the 2023 iGEM Competition team at Technische Universität Braunschweig (TU_BS) to aid their pioneering research into lithium therapy toxicity testing.

From INTEGRA Biosciences 8 Mar 2024

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

5 Mar 2024

PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases

New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions.

From PharmaKure 29 Feb 2024

Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production

Rapid, Sensitive, and Validated Detection of Viral Replication Genes Using Droplet Digital™ PCR During Cell and Gene Therapy Production.

From Bio-Rad Laboratories 27 Feb 2024

Optibrium launches a metabolism prediction software platform tailored to DMPK scientists

Semeta™ offers high sensitivity and superior precision for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discove.ry

From Optibrium Ltd. 27 Feb 2024

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

23 Feb 2024

Developing a novel norovirus vaccine candidate with INTEGRA pipettes

INTEGRA Biosciences has awarded 50 EVOLVE manual pipettes, GRIPTIPS® pipette tips worth US $1000 and various lab accessories to HilleVax, helping to advance its pioneering research into norovirus vaccine development.

From INTEGRA Biosciences 23 Feb 2024

Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development

Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease

From Aptamer Group 22 Feb 2024

INTEGRA's innovative modules simplify magnetic bead purification workflows

INTEGRA Biosciences is excited to announce the launch of its MAG and HEATMAG modules for efficient, automated magnetic bead purification.

From INTEGRA Biosciences 22 Feb 2024

LabVantage’s Professional Services Organization Grows by More than 80% in Three Years and Expands Globally

Global expansion of resources, availability, and knowledge enables LabVantage to significantly reduce implementation timelines and support customers anywhere in the world.

From LabVantage Solutions 22 Feb 2024

MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space

Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients.

From MIP Discovery 20 Feb 2024

ARRALYZE® launches CellShepherd®: A fully autonomous single-cell platform for real-time monitoring of functional assays

ARRALYZE®, the Life Science arm of LPKF Laser & Electronics SE, proudly announces the commercial availability of the CellShepherd®.

From Arralyze 12 Feb 2024

Aspen Biosciences launches Pipeline, the program management software platform specifically for drug discovery. The groundbreaking ‘Pipeline’ Platform is now available for therapeutics development teams

Aspen Biosciences, a leading provider of custom software, and integrations for drug discovery companies, is excited to announce the launch of Pipeline, the drug discovery program management software platform.

9 Feb 2024